Malaria-Transmitting Parasites Seem To Be Hampered By Minestrone And Other Soups : Goats and Soda – NPR

It could be that malaria-carrying parasites are rendered less potent by minestrone. hmproudlove/Getty Images hide caption

It could be that malaria-carrying parasites are rendered less potent by minestrone.

Bring in some soup.

The unusual homework assignment at London's Eden Primary School was for a science week project cooked up by parent Jake Baum. He's a professor of cell biology and infectious diseases at Imperial College London, and his lab's job is to find new ways to combat malaria, which kills half a million children each year.

Baum figured he could teach young students about the process of medical research through something both tasty and understandable: the go-to soup recipes their families use when someone gets sick.

"What makes a good medicine versus hocus-pocus?" explains Baum, who regularly preps his own favorite home remedy, something he calls "Jewish grandmother's chicken soup."

"It was not the plan to discover anything," he adds.

Sixty students transported their soup submissions to school in 15 milliliter plastic tubes. That's about 1 tablespoon. The soup was frozen, thawed (standard practice for samples) and then (much to the children's delight) centrifuged spun in a machine to separate different substances.

At the next step, filtration, four samples were determined to be too dense or oily to test. Although they were likely delicious, they didn't make it to the lab stage, where the remaining 56 samples were tested in two ways against the P. falciparum parasite the species responsible for 99% of malaria deaths.

First, researchers checked what effect the soups had on asexual growth during the disease-causing stage. Or, to put it in primary school terms, they were looking through the microscope for the color green.

"More green means [the parasites are] happy. With an inhibitor like a drug, it's less green," Baum says. They followed up by checking on male parasite sexual development, which is responsible for disease transmission. For that, they recorded the movement of the parasites because, as Baum notes, "sperm wiggle."

To Baum's surprise, with five of the soups, the color green was much dimmer five of them were able to suppress growth by over 50% (and two of these even did about as well as a leading antimalarial, dihydroartemisinin).

In other soups, there was a lot less wiggling. Four were found to have blocked transmission activity by more than 50%.

"We just said, 'Wow, what do we do with this?' " Baum says.

The answer turned out to be another teachable moment for the students, ages 4 to 11, who participated in the study. Although the results were collected within a few months, it took two years for the work to get published. Another Eden Primary parent, pediatric nephrologist Stephen Marks, helped pitch the study to journals and championed the idea that the children of the school should be listed as authors which they were when the study was finally released in November in the Archives of Disease in Childhood.

"Every kid can say they've had their first scientific paper," says Baum, who jokes that some may want to turn it into a paper airplane.

But it was a project they're likely to remember, notes Susanna Daniels, another parent/scientist, who also happens to be a soup enthusiast. As soon as her two children in the school came home to tell her about the experiment, there was some hypothesizing going on. "Our oldest was most disappointed because I'm a pescatarian. She was anxious our soup would fail because it wasn't chicken soup," explains Daniels, who opted to make her mother's veggie minestrone, loaded with cabbage, carrots, celery and tomato.

Turns out, that combo did especially well in the study, accounting for two of the samples that helped block transmission activity. "It wasn't a fluke finding because it was duplicated in both samples," Daniels says. The kids were thrilled to get the news, she adds. "They wanted to ring my mum straight away. She was quite bemused by the whole thing."

It's not so far-fetched to search for medical breakthroughs in your grandma's or great uncle's kitchen concoctions, Baum says, pointing to the scientific literature extolling the curative properties of chicken soup. (Research studies like this one suggest that it curbs some symptoms of upper respiratory tract infections.)

In terms of malaria treatment, the original lifesaving medicine was quinine, found in the bark of the South American cinchona tree. Today, the most commonly recommended anti-malaria drugs are derived from the artemesia plant (aka wormwood), which has been prescribed in traditional Chinese medicine for over 1,000 years. As Baum says, "Nature can produce fantastic molecules."

Pinpointing what exactly it was about these specific soups that had an effect would take years of additional research. For starters, it's hard to even tell what was in them. A bright red one probably contained beets, and a lot of them smelled like chicken. But students were never asked for a list of ingredients. Even though some kids had written information on the plastic tube samples they submitted, "when we wiped the tubes with ethanol, we lost the recipes," Baum says.

No one is claiming that these soups offer a promising pathway to a cure. "I'm using a lot of 'could, would, possibly,' " notes Baum, who doesn't have current plans for more soup experiments. But if he did and the resources were available he'd love to see it performed globally. Although the Eden Primary students come from diverse ethnic backgrounds, Baum says, they're all doing their grocery shopping in London. They can't pluck a leaf from a particular kind of bush the way kids in other parts of the world might.

Building on local knowledge is vital in malaria research, agrees Stephanie Yanow, a global health professor at the University of Alberta, who was not involved in the soup study. "We're at a difficult point every intervention we've tried, the parasite is always ahead of the game. Malaria numbers are going up in some places. There's drug resistance. The vaccine we have isn't very effective," she says. "We need to think outside the box and use more unconventional methods."

What struck her about the project was how well it engaged kids and their families and encourages "citizen scientists," or people without formal scientific training, to get involved in research.

And it's definitely made Yanow wonder what mysteries await in her minestrone. "There's a reason we think of it as a comfort food," she says.

Vicky Hallett is a freelance writer who regularly contributes to NPR.

Read the original:
Malaria-Transmitting Parasites Seem To Be Hampered By Minestrone And Other Soups : Goats and Soda - NPR

GE Healthcare Life Sciences pairs up with Advanced Solutions Life Sciences to create new opportunities for regenerative tissue manufacturing -…

MARLBOROUGH, Mass. & LOUISVILLE, Ky.--(BUSINESS WIRE)--GE Healthcare Life Sciences and Advanced Solutions Life Sciences (ASLS) will enter into a strategic R&D and distribution partnership that sets out to personalize tissue regeneration. The integration of IN Cell Analyzer and BioAssemblyBot systems technologies will embed cellular-level assessments into the 3D-bioprinting workflow used to create human tissue models.

Bioprinted tissues are small in size and die quickly, due to an inability to engineer small blood vessels the bodys supply network. ASLS patented Angiomics technology enables bioprinted microvessels to self-assemble into functional capillary beds, which deliver nutrients, oxygen, and hormones to the 3D tissue model and remove waste. This partnership would allow life scientists and tissue engineers to quickly design, build and image living, vascularized 3D tissues in a single, agile process.

Emmanuel Abate, General Manager of Genomics & Cellular Research, GE Healthcare Life Sciences, says: Printing multi-material 3D objects inside of microwell plates allows scientists to efficiently move away from traditional 2D monocultures on plastic, to 3D discovery and cytotoxicity models that more accurately reflect native biology and disease. By combining this flexibility and precision of the BioAssemblyBot with the image quality and speed of the IN Cell Analyzer 6500 HS confocal screening platform, the prospect of automating high content screening in 3D models can become a reality.

Currently, biopharmaceutical companies test their drugs in 2D models and animal models. Precise 3D models provide a more physiologically relevant environment for drug testing because they mimic human reactions.

The power of both of these platforms brings a new level of efficiency, speed and quality with assay designs and 3D biofabrication, says Michael Golway, President & CEO of ASLS.

Traditional 3D bioprinters are not designed for quality or interoperability with the high-throughput screening methods that pharmaceutical developers use to identify drug candidates. This alliance will result in a new product to address this challenge: an integration of GE Healthcare Life Sciences IN Cell Analyzer confocal imaging platform with IN Carta cell analysis software, and ASLS BioAssemblyBot 3D bioprinter with TSIM design software.

For pharmaceutical companies, where the average time to develop a new drug candidate may take over seven years, moving from traditional stage-gate testing processes to a lean, agile workcell for 3D tissue fabrication and assessments will shorten development timelines. The integration between IN Cell Analyzer and BioAssemblyBot enables the automated inclusion of cellular imaging information into the tissue modeling process so that new therapies can be scaled more quickly and effectively.

To learn more, please go to http://www.lifesciences.solutions/GE

For a live demonstration visit booth #908 at the joint meeting of the American Society of American Cell Biology (ASCB) and the European Molecular Biology Organization in Washington, DC taking place from December 7-11, 2019.

About GE Healthcare Life Sciences:

GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.

About Advanced Solutions Life Sciences:

Advanced Solutions Life Sciences (ASLS) is dedicated to the discovery, design, and development of integrated software and hardware solutions for the fields of science that involve living organisms, molecular biology, and biotechnology. ASLS offers a full-service business model including its patented, cGMP and UL certified BioAssemblyBot platform, as well as BioBot Basic, TSIM and BioApps Software, VIPM, and Professional Services. Visit http://www.bioassemblybot.com for more information.

See the original post here:
GE Healthcare Life Sciences pairs up with Advanced Solutions Life Sciences to create new opportunities for regenerative tissue manufacturing -...

Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug…

DetailsCategory: AntibodiesPublished on Monday, 09 December 2019 18:35Hits: 253

CAMBRIDGE, MA, USA I December 09, 2019 IMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC patient preparation program were presented at the 61st Annual Meeting of the American Society of Hematology (ASH). These results, which were highlighted in an oral presentation at ASH by John Tisdale, M.D., Director, Molecular and Clinical Hematology Section, National Institutes of Health, showed the first-ever successful transplant of gene-modified cells in non-human primates using a targeted, single-agent antibody-drug conjugate (ADC), without the use of chemotherapy or radiation.

Todays conditioning regimens involve high doses of chemotherapy, often paired with radiation, to remove the disease-causing cells. As a result, patients undergoing gene therapy or stem cell transplant are all faced with a difficult choice: whether to endure severe toxicity and risk infertility and cancer for the chance for a cure. Magentas portfolio of targeted ADCs represents an extremely promising new option to prepare patients for gene therapy or transplant with no need for toxic chemotherapy or radiation, said Dr. Tisdale. The results presented today show that a single dose of single agent CD117-ADC achieves the same level of depletion as four doses of busulfan chemotherapy to enable successful engraftment and persistence of stem cells modified with the -globin gene, the gene that causes sickle cell disease and -thalassemia when mutated. Importantly, the animals undergoing preparation with CD117-ADC showed none of the damaging toxicities associated with busulfan conditioning.

Magenta is the only company with the people, platforms and a product engine committed to comprehensively transforming immune and blood system reset, which includes revolutionizing the toxic methods that are used to prepare patients for gene therapy and transplant today. said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. The gene therapy field has learned that higher levels of stem cell depletion, which meant higher doses of busulfan, were needed to ensure long-term engraftment of the gene-modified cells and persistence of gene therapy. Across all the modalities we have tested, we have seen that ADCs are most effective at achieving these high levels of stem cell depletion without chemotherapy to enable engraftment and long-term durability of the transplant. Todays impressive results provide important validation of the ADC approach as well as the CD117 target for patient preparation and underscore Magentas leadership in the field of conditioning.

Results from the CD117-ADC Patient Preparation Program

Title: A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates (Abstract #610) Presenter: John Tisdale, M.D., Director, Molecular and Clinical Hematology Section, National Institutes of Health, Bethesda, Md.

Magentas most advanced patient preparation program, CD117-ADC, targets CD117, a protein expressed on hematopoietic stem cells. CD117-ADC is designed to remove the genetically mutated cells in the bone marrow that cause certain genetic diseases, such as sickle cell disease, enabling curative stem cell transplant or gene therapy.

Results presented by Dr. Tisdale showed:

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

SOURCE: Magenta Therapeutics

More:
Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug...

ERC promotes CRISPR research to better treat infections – News-Medical.net

Chase Beisel heads the "Synthetic Biology of RNA" research group at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Wrzburg, a branch of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and run in collaboration with the Julius-Maximilians-Universitt in Wrzburg. With the Consolidator Grants, the European Research Council (ERC) promotes research by up-and-coming scientists in Europe.

CRISPR is a word on everyone's lips at the moment. Although it sounds somewhat crispy and delicious, it is in fact inedible - it is actually one of the most promising tools of genetic engineering. CRISPR stands for "Clustered Regularly Interspaced Short Palindromic Repeats". These short DNA segments in the genome of bacteria are named after their regular pattern of repeating and mirrored sequences. They act as effective virus defence systems for bacteria. Copies of the CRISPR DNA exist in the form of RNA fragments in the cell. In the event of a viral attack, where a virus injects its DNA into a bacterium, the defence mechanism is triggered: The proteins, which include Cas9, is called to action and compares the sequence of the foreign DNA with that of the CRISPR RNA fragments. If it finds a matching counterpart, Cas9 cuts the foreign virus DNA, thus rendering the intruder harmless. The CRISPR-Cas9 system is therefore also known as genetic scissors and is now used for genome editing. DNA sequences can be specifically cut and modified in the laboratory using custom-designed CRISPR gene scissors, for example for the development of improved crops or medicines, for the manufacture of industrially used microorganisms, and in human cells for treating genetic diseases.

American chemical engineer Chase Beisel dedicated himself to CRISPR research around nine years ago. "We have an incredibly powerful genetic engineering tool at our disposal," says Beisel. "In order to fully and safely utilise its potential in the future, it is important that we better understand the basic biological relationships of CRISPR complexes in bacteria." The bacterial immune system can evidently learn new things and arm itself against other attackers by quickly integrating parts of foreign DNA into its own genome. CRISPR arrays encode the memory of previous infections and enable multiple intruders to be attacked simultaneously. How exactly these advanced CRISPR complexes are created, which criteria are used for selecting new sequences and which key genes of the attacker are thus rendered ineffective are not yet fully understood. This is exactly where Beisel's current research project "CRISPR Combo" aims to start, addressing the unanswered questions. "In addition to researching the biological fundamentals of CRISPR arrays in bacteria, we would also go one step further in the direction of a genetic application of CRISPR arrays," says Beisel. "To do this, we will use designed CRISPR arrays to target multiple genes at once in pathogens, thereby identifying combinations that most drive infections and providing new drug targets."

In 2018, Beisel moved from the Department of Chemical and Biomolecular Engineering at the North Carolina State University in Raleigh (USA) to the HIRI in Wrzburg, where he has been the head of the "RNA Synthetic Biology" research group for two years now. His twelve-person team consists of postdocs, doctoral candidates, technicians and students. "The funding from the ERC means I can confidently add four members to the team - that is really fantastic," says Beisel. "The ERC Grant is an important milestone for me personally. Making the leap to Germany to join the HIRI was absolutely the right decision, and I am delighted about this funding. It enables me to dedicate my research to a topic that fascinates me and at the same time offers significant benefits for society as a whole."

Posted in: Medical Science News | Medical Research News | Disease/Infection News

Tags: Bacteria, Cas9, Cell, CRISPR, DNA, Gene, Genes, Genetic, Genetic Engineering, Genome, Genome Editing, Hospital, Immune System, Laboratory, Palindromic Repeats, Research, Research Project, RNA, Virus

Continued here:
ERC promotes CRISPR research to better treat infections - News-Medical.net

Biochemistry Analyzers Market: A Latest Research Report to Share Biochemistry Analyzers Industry Insights and Dynamics By 2026 – Market Strategies

The research report on the global Biochemistry Analyzers marketprovides a comprehensive outlook of the equipment and technological devices employed in the manufacturing of the Biochemistry Analyzers market products. From industry chain analysis to cost structure analysis, the report examines various factors of the industry, including production and end-use segments of the Biochemistry Analyzers market. The current trends in the pharmaceutical industry have been highlighted in the report to evaluate their influence on the overall output of the Biochemistry Analyzers market. The Biochemistry Analyzers Market analyzed in this study is speculated to grow at a CAGR of XX% during the forecast period (2019-2026).

Fill in your details to get your hands on an Exclusive Sample of this Report @ https://www.marketexpertz.com/sample-enquiry-form/71860

Competitive Landscape:

The Biochemistry Analyzers market is moderately competitive and includes numerous key players. When looking at market share, few industry players predominantly constitute the worldwide market. With the growing awareness among patients and high prevalence of diseases like cancer, new companies are also expected to find their way into the market in the near future.

Some of the major players engaged in the market are :

Roche Diagnostics GmbH, Siemens AG, Beckman Coulter Inc., Abbott Diagnostics Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic, Inc., Randox Laboratories Ltd., Awareness Technology, Inc., Transasia Biomedicals Ltd, Nova Biomedical Corp.

Results of the latest scientific undertakings for the development of new Biochemistry Analyzers products have also been considered. Factors that can potentially influence the leading industry players to implement synthetic sourcing of market products have also been studied in this investigative report. The inferences drawn in this study are valuable for any company operating in the industry. Every organization contributing to the global production of the Biochemistry Analyzers market products has been profiled in this report, in order to study the insights on cost-effective manufacturing methods, competitive landscape, and new avenues for applications.

Biochemistry Analyzers Market Segmentation:

Type of Biochemistry Analyzers Market:

Semi-automated Biochemistry Analyzer, Fully Automated Biochemistry Analyzer

Application of Biochemistry Analyzers Market:

Clinical Diagnostics, Bioreactor Byproduct Detection, Drug Development Applications, Others

Grab Your Report at an Impressive Discount! Please Click Here @ https://www.marketexpertz.com/discount-enquiry-form/71860

The varying scenarios across the global market have been examined in this study, providing an overview of how the Biochemistry Analyzers products have established their place in this rapidly-evolving sector. Industry participants will be able to formulate their strategies and tactics by assessing the speculated market size for the forecast mentioned in the report. Favorable regional markets for the Biochemistry Analyzers have been described, which are expected to impact the global expansion strategies of the leading organizations. Additionally, key manufacturers have been profiled comprehensively in this research report.

In market segmentation by geographical regions, the report has analyzed the following regions-

North America

Europe

China

Japan

Middle East & Africa

India

South America

Others

With the existing market standards evaluated, this research report also explains the latest strategic initiatives and patterns of the market players in an unbiased way. The report can be construed as a presumptive business record that can aid the readers functioning in the global market devise their plans effectively, to reach the desired position in the market in the forecast period.

Read the Comprehensive Report with a meticulous TOC and panoramic coverage of the [emailprotected] https://www.marketexpertz.com/industry-overview/biochemistry-analyzers-market

Report Methodology:

The data contained in this report has been derived through both primary and secondary research methodologies.

Primary research methodology includes interaction with service providers, suppliers, and industry professionals. Secondary research methodology entails a thorough examination of relevant literature like company annual reports, financial reports, and exclusive databases.

This report provides:

Request customized copy of Biochemistry Analyzers report

We are grateful to you for reading our report. If you wish to find more details of the report or want a customization, contact us. You can get a detailed information of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Need to customized? Ask Our Expert @ https://www.marketexpertz.com/customization-form/71860

Continued here:
Biochemistry Analyzers Market: A Latest Research Report to Share Biochemistry Analyzers Industry Insights and Dynamics By 2026 - Market Strategies

Biochemistry Analyzers Market to Receive Overwhelming Hike in Revenues by 2026 – Montana Ledger

GlobalBiochemistry Analyzers Market: Overview

The report details an exhaustive account of the global biochemistry analyzers market along with numerous associated factors. Some of these factors that are included in the report are drivers, restraints, competitive analysis, latest trends and opportunities, geographical outlook, and many other aspects. The study covered in the report spans a forecast period from 2018 to 2028. From an overall perspective, the report is expected to exist as a valuable insight to businesses which are already operating in the global biochemistry analyzers market, as well for those who intend to newly establish themselves in this environment.

GlobalBiochemistry Analyzers Market: Market Potential and Restraints

Widespread advancements in the medical field have primarily been responsible for driving the global biochemistry analyzers market. Moreover, with rising geriatric population, the numbers of health issues are gradually increasing, thereby increasing demand for relevant treatments that involve biochemical analyzers. In addition, these analyzers possess a high rate of identification of a specific pathogen, consequently providing high clarity and accuracy.

Request Brochure of Biochemistry Analyzers Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50526

These characteristics make the use of the biochemical analyzers more suitable than other alternatives, thereby boosting growth in the global biochemical analyzers market. Technological advancements are expected to increase even more in the near future, consequently projected to further stoke expansion in the global biochemical analyzer market. Increasing use of the analyzers in drug monitoring, drug abuse detection, and drug provision, owing to rise in the number of health conditions too is notably contributing towards growth witnessed by the global biochemistry analyzers market.

However, this market is hindered owing to several factors. A prominent obstacle present in its growth involves lack of expertise and shortage of necessary manpower required to provide the treatments that involves use of biochemistry analyzers in remote and underdeveloped regions. Owing to this, the market remains restrained geographically. Moreover, high costs of manufacturing the analyzer compounds might cause difficulties for small-scale healthcare centers to afford the required equipment.

In addition, there are several complexities involved with carrying out medical processes that make use of the analyzers. Due to this, people might prefer traditional and cheaper alternatives, which is notably hampering progress in the global biochemistry analyzers market. Nonetheless, key players are soon expected to introduce cost-effective analyzer production procedures, thus blanketing most restraints affecting the global biochemistry analyzers market.

Request for a Discount on Biochemistry Analyzers Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=50526

GlobalBiochemistry Analyzers Market: Geographical Outlook

This market is mainly spread across North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Of these, a strong medical infrastructure in North America has made this region hold a leading stance with maximum market share. Many organizations are growing in the global biochemistry analyzers market in North America owing to the availability of necessary funds, mainly to conduct research and develop new and efficient treatments. However, apart from North America, Asia Pacific too showcases a splendid growth present in the global biochemistry analyzers market. This is majorly due to the introduction and utilization of various treatment procedures wherein biochemistry analyzers play a huge role. In addition, several companies are pouring extensive investments in developed economies located in Asia Pacific, which is anticipated to strengthen the market in this region.

GlobalBiochemistry Analyzers Market: Competitive Landscape

This market depicts the presence of a substantially competitive vendor landscape, with the presence of a handful of players exerting their respective dominance. Regulation of treatment costs, achieving geographical expansion, and bringing forth medical treatment efficiency are key strategies implemented by most players operating in the global biochemistry analyzers market. Abbott Diagnostics Inc., Hologic, Inc., Transasia Biomedicals Ltd., Beckman Coulter Inc., Roche Diagnostics GmbH, Siemens AG, Randox Laboratories Ltd., Awareness Technology, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and Nova Biomedical Corp., are chief players operating in this sector.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.com

Read the original:
Biochemistry Analyzers Market to Receive Overwhelming Hike in Revenues by 2026 - Montana Ledger

Researcher who uncovered the sex life of marsupials awarded Academy’s most prestigious medal – Australian Academy of Science

December 09, 2019

A scientist whose research has transformed our understanding of Australias iconic mammals has been recognised by the Australian Academy of Science. Professor Marilyn Renfree AO FAA has been awarded the Academys highest honour in the biological sciencesthe Macfarlane Burnet Medal and Lecture.

For half a century the committed reproductive and developmental biologist and conservationist from the University of Melbourne has been using the tammar wallaby, a small macropodid marsupial native to South and Western Australia, to study their reproduction and development.

Professor Renfree has developed contraceptive strategies for kangaroos and koalas and established marsupials as unique biomedical models for understanding human reproduction.

She is now a world authority on marsupial reproduction and development and has pioneered research on some of Australias most iconic creatures including kangaroos, koalas and now echidnas.

And with passion for her work as strong as ever, she has no plans of slowing down. Professor Renfree has just embarked on the worlds first study of the development of the embryo and newly hatched pouch young from the echidna.

Professor Renfree said hardly anything was known about marsupials when she started out.

Im passionately Australian and I really wanted to work on something Australian but when I started honours I said to my prospective supervisors: I wanted to do biochemistry and fieldwork. And they laughed at me. Well, Im still really doing biochemistry and fieldwork.

Her first paper published from her PhD in 1972 was aNaturepublication.

In her distinguished career Professor Renfree has made numerous research breakthroughs. In research with colleagues Professor Renfree conducted the first genome sequencing of an Australian marsupial, the tammar wallaby, providing new information on their evolution.

She also showed that certain genes directly control sexual development during pregnancy and even after birth in marsupials, providing a new understanding of the relative influence of genes versus hormones in sexual differentiation in all mammals. With colleagues she also discovered a new hormone pathway that explains some human disorders of sexual development.

Professor Renfree said Australia is sitting on a biological goldmine because it is home to a unique assembly of mammalsthe marsupials and monotremes.

The impact of Australias recent bushfires on Australian mammals has highlighted Australia and the worlds fascination with these special animals. We really need to put more effort, time and money into conserving and doing research on them, Professor Renfree said.

Australia has the distinction of having the worst record of mammal extinctions of any developed country and thats not a record you want to be proud of.

Professor Renfree said the Academy award is a huge honour.

Im receiving it on behalf of all of my students, PhD students and postdocs and collaborators. Without them I could have only done a fraction of what I've done, Professor Renfree said.

She was nominated for the medal by Professor James Angus FAA from the University of Melbourne.

Professor Renfree is a pioneer and forward thinker who has an ability to excite and inspire scientists from around the world by providing new insights through the study of the unique evolutionary innovations in the reproductive systems of marsupials and monotremes, Professor Angus said.

The basic science and the clinical impact of her work for humans are as important as the direct benefits of her work for Australias marsupials. Her research has undoubtedly opened the eyes of the academic world and beyond to the value of these iconic Australian mammals both for their intrinsic interest and as unique biomedical models.

Professor Renfree will receive the medal and give a lecture at the Academys Science at the Shine Dome event in May 2020. The Macfarlane Burnet Medal and Lecture honours the contributions to science by Sir MacFarlane BurnetOMKBMDFAAFRSNobel Laureate.

See the original post here:
Researcher who uncovered the sex life of marsupials awarded Academy's most prestigious medal - Australian Academy of Science

Introducing the Autophagy and Proteostasis Collection – PLoS Blogs

The importance of proteostasis is becoming increasingly apparent as disrupted proteostasis and dysregulation of proteostasis-associated networks has been linked with aging and many age-associated diseases such as Alzheimers, Parkinsons and Huntingtons disorders. In recognition of the importance of this subject, PLOS ONE, alongside PLOS Biology, launched a Call for Papers on the topic of Autophagy and Proteostasis earlier this year. We welcomed a range of submissions that provided insight into the molecular and cellular machinery, and mechanisms that regulate autophagy and the crosstalk of this process with other protein quality control pathways to ensure proteostasis. These studies also underline the importance of all these cellular pathways in pathophysiological conditions and aging. The Guest Editors are Sharon Tooze (Francis Crick Institute, United Kingdom), Fulvio Reggiori (University Medical Centre Groningen, The Netherlands) and Thorsten Hoppe (Institute for Genetics and CECAD Center for Aging Research, University of Cologne, Germany).

We are happy to launch this Collection today, which includes five studies published in PLOS ONE that highlight the relevance of autophagy and other pathways such as the ubiquitin proteasome-system in maintaining protein homeostasis. In human cells, Ferreira et al. showed that when the STUB1/CHIP ubiquitin ligase is inactivated, cells increase secretion of extracellular vesicles (EVs) enriched in ubiquitylated or stabilized proteins, suggesting that cells use these EVs to dispose of proteotoxic material. Studying another E3 ubiquitin ligase, Si and colleagues investigate the mechanism for Pink1- and Parkin-mediated mitophagy in indirect flight muscles in Drosophila melanogaster, and showed that Pink1/Parkin are crucial for muscle function in aged muscles in an Atg1-dependent manner. Autophagy also plays crucial roles in the fungus Aspergillus niger and Kaur and Punekar revealed that acidogenic growth appears to mimic a nutrient deficient condition, and acidogenic growth and metabolism are compromised in atg1 and atg8 strains of A. niger.

In addition, two papers in the Collection showcase research investigating proteostasis dysfunction in disease states, and potential ways to modulate autophagy for therapeutic uses. Aviazidis et al. study proteostasis network dysfunction caused by unbalanced karyotypes using human Downs syndrome fibroblasts, showing that decreased abundance of SNARE family members STX17 and VAMP8 maybe responsible for reducing autophagic flux by impairing autophagosome-lysosome fusion. Bhaskar et al. identify lipoarabinomannan (LAM), a crucial lipid component of the Mycobacterium indicius pranii cell-wall, as an inducer of autophagy that leads to the enhancement of co-localization between Mycobacteriaum tuberculosis and phago-lysosomes, and increased clearance of this bacterium in macrophages.

Papers will continue to be added to the Collection as they are published. Stay tuned for new articles and additional insights on this important topic.

Fulvio Reggiori

Fulvio Reggiori is a Professor and Section Head of Molecular Cell Biology at the Department of Biomedical Sciences of Cells and Systems of the University Medical Centre Groningen, The Netherlands. Fulvio obtained in his PhD in Biochemistry from the University of Fribourg, Switzerland, in the laboratory of Professor Andreas Conzelmann. Subsequently, he moved to the MRC Laboratory in Molecular Biology in Cambridge to join the laboratory of Dr. Hugh Pelham, UK in 1998. In 2001, Fulvio moved to the University of Michigan in Ann Arbor, USA to the laboratory of Professor Daniel Klionsky, where he started working on different aspects of the molecular mechanisms of autophagy in yeast. In 2005 he was appointed as an Assistant Professor at the Department of Cell Biology of the University Medical Center Utrecht, The Netherlands before becoming an Associate Professor in 2011. Fulvio moved his lab in 2015, to the Department of Department of Biomedical Sciences of Cells and Systems of the University Medical Center Groningen where he became Professor. His research continues to investigate the molecular mechanisms of autophagy using Saccharomyces cerevisiae as a model organism as well as understanding the interaction between autophagy and pathogens, in particular viruses.

Sharon Tooze

Sharon Tooze is a Senior Group Leader at the Francis Crick Institute, London, UK. She has a long-standing interest in understanding organelle biogenesis using molecular cell biology approaches. Sharon received her PhD and undertook a postdoctoral research position in Wieland Huttners lab at the European Molecular Biology Laboratory (EMBL). She established a lab at Imperial Cancer Research Fund, UK which later became known as the Cancer Research UK London Research Institute. In 2015 she moved her lab to the Francis Crick Institute where her research continues to focus on autophagy. Her current interests are focused on expanding our knowledge of the core autophagy proteins in mammalian cells at the molecular level, in particular the autophagy proteins which initiate the formation of the autophagosome.

Thorsten Hoppe

Thorsten Hoppe is a Professor at the Institute for Genetics and the Center for Aging Research (CECAD) at the University of Cologne, Germany. He received his PhD from the University of Heidelberg working in the lab of Stefan Jentsch at the Center for Molecular Biology in Heidelberg (ZMBH) and the Max Planck Institute of Biochemistry in Martinsried. He undertook is postdoctoral work in the Department of Molecular Neurogenetics in the group of Ralf Baumeister at the LM-University of Munich before setting up his own group in 2003 at the Centre for Molecular Neurobiologie at the University of Hamburg (ZMNH). In 2008 he moved his lab to the Institute for Genetics and was Acting Director from 2011 to 2013. His research focuses on understanding the role proteostasis plays in aging and age-associated diseases.

Go here to see the original:
Introducing the Autophagy and Proteostasis Collection - PLoS Blogs

Koeppe Recognized for Service as ABI Institutional Director at University of Arkansas – University of Arkansas Newswire

Chieko Hara, University Relations

From left, Dan Sui, vice chancellor for research and innovation; Roger Koeppe, Distinguished Professor of chemistry and biochemistry; and Robert "Bobby" McGehee, executive director of Arkansas Biosciences Institute and dean at UAMS Graduate School

Science and engineering researchers at the University of Arkansas use research awards from the Arkansas Biosciences Institute to improve the health of Arkansans and prevent smoking-related illnesses.

Seed funding from the institute, a statewide consortium consisting of five research institutions, often enables researchers to produce preliminary results that help them and the university compete for large grants from federal agencies, such as the National Science Foundation and the National Institutes of Health.

As the U of A's institutional director and ABI representative for 11 years, Roger Koeppe, Distinguished Professor in the Department of Chemistry and Biochemistry, helped many colleagues secure funding from the institute. Koeppe was recognized for his service Thursday during a faculty town hall meeting to discuss future funding priorities and strategies of the Arkansas Biosciences Institute. The meeting was hosted by Dan Sui, vice chancellor for research and innovation.

"ABI funds have made a huge difference on this campus, certainly in terms of biosciences research, but also as leverage to attract and recruit top investigators," Sui said. "Obviously, Roger has been responsible so much its success on this campus, and we want to recognize his enormous contribution."

Earlier this semester, Chancellor Joe Steinmetz appointed Sui to serve as the new ABI institutional director.

The Arkansas Biosciences Institute was established as a result of Arkansas' share of the 1998 nationwide tobacco settlement. Health care leaders in the state sought a productive way to disperse the state's share of the settlement. TheArkansas Biosciences Institutewas created as a conduit for research that could help reduce or prevent smoking-related illnesses.

Arkansas voters endorsed the proposed Tobacco Settlement Proceeds Act of 2000, and the Arkansas Legislature enacted the provisions of that proposal as Acts 1569 through 1580 of 2001. Part of that legislation established the institute as a consortium of five research institutions: the University of Arkansas, the University of Arkansas System Division of Agriculture, the University of Arkansas for Medical Sciences, Arkansas State University and Arkansas Children's Hospital. Since ABI's beginning, scientists at these institutions have focused on biomedical and agricultural research with medical implications.

Robert "Bobby" McGehee, executive director of the Arkansas Biosciences Instituteand dean at University of Arkansas for Medical Sciences Graduate School, also recognized Koeppe during Thursday's meeting. He and Koeppe served together for more than a decade.

McGehee said Arkansas is one of only two states that uses all of its tobacco settlement money for heath inititatives and healthcare research. Sui said the university will continue to use ABI funds to make new strategetic investments in biosciences research.

Link:
Koeppe Recognized for Service as ABI Institutional Director at University of Arkansas - University of Arkansas Newswire

Does the ‘genetics revolution’ unsettle you? Here is a guide, and reasons to be hopeful – Genetic Literacy Project

Its that time of year again an avalanche of ads urging us to drool into tubes so companies can spit back verdicts on our pasts, presents, and futures. Judging from my emails, those unceasing ads have inspired many questions about genetics in general.

Among the emails that pinged in recently:

So I started a list of my e-mails, with apologies to Hillary, and extracted three recurring themes: transgender identity, when a human life begins, and by far the largest group: interpreting DNA test results, either consumer or clinical.

What do you think about a new studythat found 20 genetic markers of transgender identity? asked a reporter from The Times of London In March 2018. Id suggested just such a study a year earlier, which hed found here.

Impressed with the study, I agreed to comment. But the reporter forgot to distinguish me from the researcher, and so throughout Europe, I was suddenly an expert on transgender genes. And that inspired some telling emails.

The first, from a trans woman born in 1948, shared her 70-page story:

As far back as I can remember I thought nothing of going into my mothers closet, pulling down her nightgowns, and putting them on. They were soft, they smelled of her, and they felt so perfect. This was me. Everything feminine fascinated me. Anything male repelled me. I wanted to emerge myself in the female world. But no matter what I did, I just couldnt look like Mommy.

Another transgender woman wrote:

I would love to have that degree of certainty that a genetic study would show. Parents would be able to perhaps work with their children instead of ignoring it either intentionally or out of ignorance.

A recent email from 58-year-old Edith brought up nature v nurture:

Two of my nine nieces and nephews are transitioning. My family has an overall fluid concept of gender identity, which we discussed with each other before either child made it known they were trans. I find myself wondering if this is true in other families.

Me too.

I repost 17 timepoints whenever womens reproductive rights are threatened, or I read or hear a comment that indicates ignorance of biology. The idea of the list came to me when considering that an embryos genome turns on at day 5, but it cant possibly exist at that point outside of a womans body.

One woman asked about fetal rights. Her ex had given her an herbal abortion tea without her knowledge when she was pregnant. Her baby so far is healthy, but she wants a court to recognize the tea-poisoning as child abuse. At what point in utero does a fetus have rights? It seems to vary state to state, she wrote.

Celia Collias, a statistics major at the University of North Carolina, offered a compelling perspective: distinguishing two types of viability. Natural ability to be physiologically independent for a human fetus is around 24 weeks. Technologically assisted viability for a human fetus is 21 weeks.

If we dont use natural viability as the cut off for reproductive rights, Ms. Collias argues, then those rights will erode as technology sets back the age of assisted viability:

Technologically assisted viability is not free. If we allow that to be the benchmark, its going to cost society a lot to care for all those fetuses where would that money come from?

Good question.

Is he really my brother? asked the woman who sent me scanned columns of genetic markers. I circled 16 of 38 that they share and sent it back: Yes.

I dont have mutations in BRCA1 or 2, so Im ok, right? I do have a mutation in ATM (or p53 or CHEK2 or PTEN or RAD51 or a few dozenothers). Inherited mutations for cancer risk go beyond the most common ones in the BRCA pair, and altogether they account for only 5 percent of cases. Yes, shes at high risk.

BRCA brings up the limited variant problem. Consumer DNA tests, for cancer or single-gene diseases, are likely to check for only the most common variants, such as a handful of mutations in the CFTR gene behind cystic fibrosis, which has more than 1,700. These health reports may provide a false sense of reassurance and should not be used for making any health decisions without confirmation testing, said Edward Esplin, MD, of Invitae, a clinical testing company, at the American Society of Human Genetics conference in October, catalyzing a flood of headlines.

I had a prenatal screen for 125 genes and one is a variant of uncertain significance. What the heck is a VUS? Do I have a mutation or not?

A VUS is a gene variant that isnt common, but hasnt shown up in someone with a disease and reported in the medical literature. Yet. I explain here.

My ethnicity estimate changed overnight. Huh? When an ancestry company adds a new group to its database of reference populations, the sections of those pie charts can shift, or a new one appear.

Im 20 weeks pregnant. The fetus has a microduplication of chromosome 18. Is that a problem? The healthy dad-to-be also had the tiny extra bit of DNA. So, no.

I just found out that I have an extra Y chromosome. Ive had severe acne since my early teens, and today Im 62 and weigh 295 pounds. Im a biker, football player, and served time for selling pot. Did my extra chromosome get me arrested?

Probably not. Being in the wrong place at the wrong time, before decriminalization, was more likely at fault.

Because most of my email brings up medical matters, heres a short guide to getting help in making sense of DNA test results related to health. (For interpreting ancestry findings, the International Society of Genetic Genealogy is an excellent resource.)

Its important to distinguish consumer DNA tests, which anyone can take by purchasing a kit and spitting or swizzling a cheekbrush, from clinical DNA tests, which a health care provider orders and the FDAs Clinical Laboratory Improvement Amendments (CLIA) regulate.

Like mushrooms materializing after a warm rain, articles, websites, books and companies are springing up to help consumers navigate test-taking and interpretation.

Finding an expert specifically trained at the graduate level in genetics a genetic counselor, PhD geneticist, or MD with genetics/genomics training is challenging because their priorities are in clinical testing, not the entertainment/education space that the consumer companies so ceaselessly promote. Other scientists may be helpful molecular biologists, biochemists but genetics as a discipline transcends DNA, including developmental, transmission, and population and evolutionary genetics too. Ancestry testing in particular melds these levels of genetics.

Assuming a sit-down with an expert to intrepret consumer DNA data isnt happening easily, here are some places to turn.

A longstanding helpful website is Genetics Home Reference, from the NIH.

A newer resource is this report from ConsumersAdvocate.org. Their researchers recently sent DNA anonymously to 9 leading consumer DNA testing companies, interpreted the data, and then wrote a detailed, clear analysis that compares the services, privacy/security measures, online resources, and cost of tests.

Consumer DNA testing is a fast-growing industry with over 26 million users worldwide. That number is expected to grow to 100 million by 2021, Sam Klau, Community Outreach at the organization, told me.

An excellent new book is DNA Nation: How the Internet of Genes is Changing Your Life, by PhD molecular biologist Sergio Pistoi. And my human genetics textbook will be out in a new edition in September. Ive added a chapter called The Genetics of Identity, inspired by having my past rewritten recently thanks to ancestry testing.

The testing company websites, like that of 23andme, provide clear and well-written info on interpreting test results. But without any prior knowledge of genetics, misinterpretation and misplaced angst can arise.

Does the average person know the difference in significance between revealing a pattern of genome-wide single-base variations (SNPs) associated with elevated risk of a trait or illness, and detecting a well-studied mutation in a single gene?

The raw data dump from consumer DNA testing can be overwhelming, and to paraphrase Elizabeth Warren: Theres a company for that. A consumer can pay to avoid bushwhacking through dense SNP forests.

Strategene, for example, is a genetic reporting tool that uses 23andMe data to identify SNPs in a few dozen well-studied, health-related genes, and not every SNP under the sun. The $45 is a sound investment; it would take hours to sort through Google Scholar to DIY. But the client needs to know about the limited variant issue of checking only for common SNPs.

(I was briefly fooled into confusing the company with 1980s biotech giant Stratagene, but its off by one letter and one capitalization. The only person named on the company website is a naturopath referred to many times as Dr., which wouldnt necessarily denote a genetics expert.)

Im curious to see how soon the medical profession catches up. Right now, genetic counselors in the US number only about 5,000. But professional organizations are stepping in. The American College of Medical Genetics and Genomics, for example, offers online continuing medical education, ACMG Genetics 101 for Healthcare Providers.

But doctors Ive encountered recently still go deer-in-the-headlights when I ask a genetics question, just to be obnoxious. And so a company like ActXmakes sense in helping medical professionals keep pace with the growing tide of patients coming in waving consumer DNA test results. The company helps physicians and patients apply 23andMe raw data to select drugs, order clinical tests to help diagnose specific conditions, and to confirm carrier status for single-gene diseases.

When I started my career as a Drosophila geneticist, mutating flies to grow legs out of their heads, I never imagined at-home DNA testing. When I started my career as a science writer and textbook author, I still couldnt have predicted at-home DNA testing. Now that its here, Im thrilled that DNA science has become so much more tangible and practical. Yet we must use the information in our strings of A, C, T, and G wisely.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

Read the original:
Does the 'genetics revolution' unsettle you? Here is a guide, and reasons to be hopeful - Genetic Literacy Project